Mogens H. Claesson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mogens H. Claesson has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Søren Buus
Department of Immunology and Microbiology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
4 shared publications Bernadette Guldager
2 shared publicationsFinn Gyntelberg
2 shared publications- Janne Nielsen
Laboratory of Cellular Immunology, Department of Medical Anatomy, Panum Institute, University of Copenhagen, Copenhagen, Denmark
2 shared publications Lene T. Skovgaard
2 shared publicationsLone Malte
2 shared publications
Latest Publications
- 27 April 2007
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 56 (11) , 1755-1763
Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope
By the use of a neural network capable of performing quantitative predictions of peptides binding to HLA-A*0201 molecules, we identified a number of nonamer peptides derived from the catalytic subunit of telomerase, human telomerase reverse transcriptase (hTERT). Five nonimmunogenic peptides with measured binding affinities for HLA-A*0201 ranging from 155 to 1,298 nM were modified at the P1, P2 and P9 positions, respectively, to achieve stronger HLA-A*0201 binding. One peptide, mp30–38 (mp30), with an L to V substitution at position 9 was subsequently found to be immunogenic in mp30 immunized HLA-A*0201/H2Kb or HHD transgenic mice. The T cell reactivity obtained was directed against both the mp30 and against the unmodified p30. Anti-mp30 specific T cells generated in HLA-A*0201 transgenic mice were dependent on TCR-CD8/MHC-I α3 binding and therefore not capable of recognizing mp30-pulsed human HLA-A*0201+ cells or murine HLA-A*0201 transfectants. In order to show reactivity against naturally processed peptide in human tumor cells, an hTERT positive HLA-A*0201 negative colon carcinoma cell line (CCL220) was transfected with an HLA-A*0201/H2Kb cDNA construct and used as target in ELISPOT and cytotoxicity assays. The data show that T cells from mp30 immunized HHD transgenic mice react specifically against the CCL220 transfectant indicating that p30 is naturally processed. In conclusion, we have identified a new CTL HLA-A*0201 restricted hTERT epitope, which is now, included in an ongoing phase 2 vaccine trial of patients with disseminated cancer.
- 27 April 2007
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 56 (11) , 1755-1763
Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope
By the use of a neural network capable of performing quantitative predictions of peptides binding to HLA-A*0201 molecules, we identified a number of nonamer peptides derived from the catalytic subunit of telomerase, human telomerase reverse transcriptase (hTERT). Five nonimmunogenic peptides with measured binding affinities for HLA-A*0201 ranging from 155 to 1,298 nM were modified at the P1, P2 and P9 positions, respectively, to achieve stronger HLA-A*0201 binding. One peptide, mp30–38 (mp30), with an L to V substitution at position 9 was subsequently found to be immunogenic in mp30 immunized HLA-A*0201/H2Kb or HHD transgenic mice. The T cell reactivity obtained was directed against both the mp30 and against the unmodified p30. Anti-mp30 specific T cells generated in HLA-A*0201 transgenic mice were dependent on TCR-CD8/MHC-I α3 binding and therefore not capable of recognizing mp30-pulsed human HLA-A*0201+ cells or murine HLA-A*0201 transfectants. In order to show reactivity against naturally processed peptide in human tumor cells, an hTERT positive HLA-A*0201 negative colon carcinoma cell line (CCL220) was transfected with an HLA-A*0201/H2Kb cDNA construct and used as target in ELISPOT and cytotoxicity assays. The data show that T cells from mp30 immunized HHD transgenic mice react specifically against the CCL220 transfectant indicating that p30 is naturally processed. In conclusion, we have identified a new CTL HLA-A*0201 restricted hTERT epitope, which is now, included in an ongoing phase 2 vaccine trial of patients with disseminated cancer.
- 1 January 2007
- Published by Wiley in European Journal of Haematology
- Vol. 78 (1) , 91-92
Immunotherapy of Cancer
- 1 January 2007
- Published by Wiley in European Journal of Haematology
- Vol. 78 (1) , 91-92
Immunotherapy of Cancer
CD4+CD25+ regulatory T cells: I. Phenotype and physiology
The immune system protects us against foreign pathogens. However, if fine discrimination between self and non‐self is not carried out properly, immunological attacks against self may be launched leading to autoimmune diseases, estimated to afflict up to 5% of the population. During the last decade it has become increasingly clear that regulatory CD4+CD25+ T cells (Treg cells) play an important role in the maintenance of immunological self‐tolerance, and that this cell subset exerts its function by suppressing the proliferation or function of autoreactive T cells. Based on human and murine observations, this review presents a characterization of the phenotype and functions of the Treg cells in vitro and in vivo. An overview of the surface molecules associated with and the cytokines produced by the Treg cells is given and the origin, activation requirements and mode of action of the Treg cells are discussed. Finally, we address the possibility that Treg cells may play a central role in immune homeostasis, regulating not only autoimmune responses, but also immune responses toward foreign antigens.
CD4+CD25+ regulatory T cells: I. Phenotype and physiology
The immune system protects us against foreign pathogens. However, if fine discrimination between self and non‐self is not carried out properly, immunological attacks against self may be launched leading to autoimmune diseases, estimated to afflict up to 5% of the population. During the last decade it has become increasingly clear that regulatory CD4+CD25+ T cells (Treg cells) play an important role in the maintenance of immunological self‐tolerance, and that this cell subset exerts its function by suppressing the proliferation or function of autoreactive T cells. Based on human and murine observations, this review presents a characterization of the phenotype and functions of the Treg cells in vitro and in vivo. An overview of the surface molecules associated with and the cytokines produced by the Treg cells is given and the origin, activation requirements and mode of action of the Treg cells are discussed. Finally, we address the possibility that Treg cells may play a central role in immune homeostasis, regulating not only autoimmune responses, but also immune responses toward foreign antigens.
CD4+CD25+regulatory T cells: II. Origin, disease models and clinical aspects
Autoimmune diseases afflict approximately 5% of the population and reflect a failure in the immune system to discriminate between self and non-self resulting in the breakdown of self-tolerance. Regulatory CD4+CD25+ T cells (Treg cells) have been shown to play an important role in the maintenance of immune homeostasis and self-tolerance by counteracting the development and effector functions of potentially autoreactive T cells. We have in the previous APMIS review described the phenotype and physiology of Treg cells. The present overview deals with the thymic origin of Treg cells and their role in disease models such as autoimmune gastritis and inflammatory bowel disease. Finally, we will consider some aspects of the therapeutic potential of Treg cells.
CD4+CD25+regulatory T cells: II. Origin, disease models and clinical aspects
Autoimmune diseases afflict approximately 5% of the population and reflect a failure in the immune system to discriminate between self and non-self resulting in the breakdown of self-tolerance. Regulatory CD4+CD25+ T cells (Treg cells) have been shown to play an important role in the maintenance of immune homeostasis and self-tolerance by counteracting the development and effector functions of potentially autoreactive T cells. We have in the previous APMIS review described the phenotype and physiology of Treg cells. The present overview deals with the thymic origin of Treg cells and their role in disease models such as autoimmune gastritis and inflammatory bowel disease. Finally, we will consider some aspects of the therapeutic potential of Treg cells.
- 24 May 2004
- Vol. 166 (22) , 2147-9
[Is placebo really powerless? Presentation of a Cochrane assessment].
- 24 May 2004
- Vol. 166 (22) , 2147-9
[Is placebo really powerless? Presentation of a Cochrane assessment].
- 16 September 2003
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 58 (4) , 404-411
Immunobiological Effects of Glucosamine In Vitro
Glucosamine (GlcN) and N‐acetyl‐d‐glucosamine (GlcNAc) were assayed in vitro for their effects on proliferation, cytotoxicity and cytokine secretion in primary and secondary mixed lymphocyte cultures (MLCs). In addition, we studied the effect of GlcN and GlcNAc on the proliferation of purified CD4+ T cells exposed to immobilized anti‐CD3 antibody. The present data show that GlcN, but not GlcNAc, inhibits CD4+ T‐cell proliferation, the generation of alloreactive cytotoxic T lymphocytes (CTLs) and the secretion of interferon‐γ (IFN‐γ) and interleukin‐5 (IL‐5) in primary MLC. In secondary T helper‐2 (Th2)‐polarized MLC, GlcN, but not GlcNAc, inhibits IL‐4 and IL‐5 secretion, whereas no effect was found on IFN‐γ secretion in Th1‐polarized MLC. Dendritic cells treated with GlcN showed a 75–80% decreased capacity for antigen cross‐presentation and allostimulation. In cellular bioassays, GlcN was shown to inhibit the stimulatory activity of IL‐4 and IL‐2, as well as the cytotoxic activity of tumour necrosis factor‐α (TNF‐α). In conclusion, GlcN suppresses unprimed T‐cell responses by interfering with antigen‐presenting cell functions and by a direct inhibitory effect on T‐cell proliferation. In addition, GlcN inhibits the secretion of cytokines in antigen‐stimulated unprimed T cells and primed Th2‐polarized cells.
- 16 September 2003
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 58 (4) , 404-411
Immunobiological Effects of Glucosamine In Vitro
Glucosamine (GlcN) and N‐acetyl‐d‐glucosamine (GlcNAc) were assayed in vitro for their effects on proliferation, cytotoxicity and cytokine secretion in primary and secondary mixed lymphocyte cultures (MLCs). In addition, we studied the effect of GlcN and GlcNAc on the proliferation of purified CD4+ T cells exposed to immobilized anti‐CD3 antibody. The present data show that GlcN, but not GlcNAc, inhibits CD4+ T‐cell proliferation, the generation of alloreactive cytotoxic T lymphocytes (CTLs) and the secretion of interferon‐γ (IFN‐γ) and interleukin‐5 (IL‐5) in primary MLC. In secondary T helper‐2 (Th2)‐polarized MLC, GlcN, but not GlcNAc, inhibits IL‐4 and IL‐5 secretion, whereas no effect was found on IFN‐γ secretion in Th1‐polarized MLC. Dendritic cells treated with GlcN showed a 75–80% decreased capacity for antigen cross‐presentation and allostimulation. In cellular bioassays, GlcN was shown to inhibit the stimulatory activity of IL‐4 and IL‐2, as well as the cytotoxic activity of tumour necrosis factor‐α (TNF‐α). In conclusion, GlcN suppresses unprimed T‐cell responses by interfering with antigen‐presenting cell functions and by a direct inhibitory effect on T‐cell proliferation. In addition, GlcN inhibits the secretion of cytokines in antigen‐stimulated unprimed T cells and primed Th2‐polarized cells.
- Open Access
- 29 January 2003
- Published by Springer Nature in Journal of Immune Based Therapies and Vaccines
- Vol. 1 (1) , 1
Tumor–associated antigens identified by mRNA expression profiling as tumor rejection epitopes
Thirteen H-2b-binding peptides derived from six potentially overexpressed proteins in p53-/- thymoma (SM7) cells were studied for immunogenecity and vaccine-induced prevention of tumor growth in mice inoculated with SM7 tumor cells. Six of the peptides generated specific CTL responses after immunization, but only two of these peptides (RAD23-31 and RAD24-31) were capable of generating a weak vaccination-induced protection against adoptive tumor growth. SM7 inoculated mice treated with a blocking antibody against the inhibitory T cell signal transducing molecule CTLA4 appeared to delay tumor take, suggesting that SM7 thymoma cells are recognized by the adaptive immune system of the host. However, prophylactic vaccination with RAD23-31 and RAD24-31 peptides combined with anti-CTLA4 Ab treatment and did not improve tumor resistance. Our data would indicate that vaccination with immunogenic peptides derived from potentially overexpressed tumor proteins, as identified by mRNA expression profiling of p53-/- thymoma cells, at best results in a weak tumor protection thus questioning this way of detection of new tumor rejection epitopes.
- 29 January 2003
- Published by Springer Nature in Journal of Immune Based Therapies and Vaccines
- Vol. 1 (1) , 1
Open AccessTumor–associated antigens identified by mRNA expression profiling as tumor rejection epitopes
Thirteen H-2b-binding peptides derived from six potentially overexpressed proteins in p53-/- thymoma (SM7) cells were studied for immunogenecity and vaccine-induced prevention of tumor growth in mice inoculated with SM7 tumor cells. Six of the peptides generated specific CTL responses after immunization, but only two of these peptides (RAD23-31 and RAD24-31) were capable of generating a weak vaccination-induced protection against adoptive tumor growth. SM7 inoculated mice treated with a blocking antibody against the inhibitory T cell signal transducing molecule CTLA4 appeared to delay tumor take, suggesting that SM7 thymoma cells are recognized by the adaptive immune system of the host. However, prophylactic vaccination with RAD23-31 and RAD24-31 peptides combined with anti-CTLA4 Ab treatment and did not improve tumor resistance. Our data would indicate that vaccination with immunogenic peptides derived from potentially overexpressed tumor proteins, as identified by mRNA expression profiling of p53-/- thymoma cells, at best results in a weak tumor protection thus questioning this way of detection of new tumor rejection epitopes.
- 7 January 2003
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 131 (1) , 34-40
CD4+ T regulatory cells from the colonic lamina propria of normal mice inhibit proliferation of enterobacteria-reactive, disease-inducing Th1-cells from scid mice with colitis
SUMMARY: Adoptive transfer of CD4+ T cells into scid mice leads to a chronic colitis in the recipients. The transferred CD4+ T cells accumulate in the intestinal lamina propria (LP), express an activated Th1 phenotype and proliferate vigously when exposed ex vivo to enteric bacterial antigens. As LP CD4+ T cells from normal BALB/c mice do not respond to enteric bacterial antigens, we have investigated whether colonic LP-derived CD4+ T cells from normal mice suppress the antibacterial response of CD4+ T cells from scid mice with colitis. LP-derived CD4+ T cells cocultured with bone marrow-derived dendritic cells effectively suppress the antibacterial proliferative response of CD4+ T cells from scid mice with colitis. The majority of these LP T-reg cells display a nonactivated phenotype and suppression is independent of antigen exposure, is partly mediated by soluble factor(s) different from IL-10 and TGF-β, and is not prevented by the addition of high doses of IL-2 to the assay culture. Functionally and phenotypically the T-reg cells of the present study differ from previously described subsets of T-reg cells. The presence of T cells with a regulatory potential in the normal colonic mucosa suggests a role for these cells in the maintenance of local immune homeostasis of the gut.
- 7 January 2003
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 131 (1) , 34-40
CD4+ T regulatory cells from the colonic lamina propria of normal mice inhibit proliferation of enterobacteria-reactive, disease-inducing Th1-cells from scid mice with colitis
SUMMARY: Adoptive transfer of CD4+ T cells into scid mice leads to a chronic colitis in the recipients. The transferred CD4+ T cells accumulate in the intestinal lamina propria (LP), express an activated Th1 phenotype and proliferate vigously when exposed ex vivo to enteric bacterial antigens. As LP CD4+ T cells from normal BALB/c mice do not respond to enteric bacterial antigens, we have investigated whether colonic LP-derived CD4+ T cells from normal mice suppress the antibacterial response of CD4+ T cells from scid mice with colitis. LP-derived CD4+ T cells cocultured with bone marrow-derived dendritic cells effectively suppress the antibacterial proliferative response of CD4+ T cells from scid mice with colitis. The majority of these LP T-reg cells display a nonactivated phenotype and suppression is independent of antigen exposure, is partly mediated by soluble factor(s) different from IL-10 and TGF-β, and is not prevented by the addition of high doses of IL-2 to the assay culture. Functionally and phenotypically the T-reg cells of the present study differ from previously described subsets of T-reg cells. The presence of T cells with a regulatory potential in the normal colonic mucosa suggests a role for these cells in the maintenance of local immune homeostasis of the gut.
- Open Access
- 1 January 2003
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 57 (1) , 21-27
Self-Peptides with Intermediate Capacity to Bind and Stabilize MHC Class I Molecules may be Immunogenic
Thirty self‐peptides were selected on the basis of their predicted binding to H‐2b molecules. The binding of peptides was ascertained experimentally by biochemical (KD measurements) and cellular [major histocompatibility complex class I (MHC‐I) stabilization] assays. A weak, but significant, correlation between KD measurements and MHC‐I stabilization was observed. Mice (n = 99) were immunized with individual peptides. Twenty‐eight peptides were found to induce peptide‐specific cytotoxic activity, and a total of 84 mice developed significant cytotoxic T lymphocyte (CTL) responses after immunization. Only one of the 21 mice immunized with high‐affinity peptides developed a peptide‐specific CTL response of 29 lytic units per 106 splenocytes, whereas 11 of the 42 mice immunized with intermediate‐affinity peptides developed peptide‐specific CTL responses at this level (P < 0.05). These observations suggest the absence of tolerance towards most MHC‐I‐restricted self‐peptides and that strong antiself immunity can be generated preferentially towards self‐peptides with an intermediate affinity for MHC‐I. These data should be considered in the design of tumour vaccines based on MHC‐I‐binding self‐peptides.
- 1 January 2003
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 57 (1) , 21-27
Open AccessSelf-Peptides with Intermediate Capacity to Bind and Stabilize MHC Class I Molecules may be Immunogenic
Thirty self‐peptides were selected on the basis of their predicted binding to H‐2b molecules. The binding of peptides was ascertained experimentally by biochemical (KD measurements) and cellular [major histocompatibility complex class I (MHC‐I) stabilization] assays. A weak, but significant, correlation between KD measurements and MHC‐I stabilization was observed. Mice (n = 99) were immunized with individual peptides. Twenty‐eight peptides were found to induce peptide‐specific cytotoxic activity, and a total of 84 mice developed significant cytotoxic T lymphocyte (CTL) responses after immunization. Only one of the 21 mice immunized with high‐affinity peptides developed a peptide‐specific CTL response of 29 lytic units per 106 splenocytes, whereas 11 of the 42 mice immunized with intermediate‐affinity peptides developed peptide‐specific CTL responses at this level (P < 0.05). These observations suggest the absence of tolerance towards most MHC‐I‐restricted self‐peptides and that strong antiself immunity can be generated preferentially towards self‐peptides with an intermediate affinity for MHC‐I. These data should be considered in the design of tumour vaccines based on MHC‐I‐binding self‐peptides.
- 1 September 2001
- Published by Wiley in Tissue Antigens
- Vol. 58 (3) , 171-180
Ligation of major histocompatibility complex class I antigens (MHC‐I) prevents apoptosis induced by Fas or SAPK/JNK activation in T‐lymphoma cells
Early apoptosis in Jurkat T‐lymphoma cells was induced by agonistic anti‐Fas Ab or by anisomycin which activates the stress kinases SAPK/JNK. Apoptosis was inhibited by ligation of major histocompatibility complex class I antigens (MHC‐I). MHC‐I ligation induced upregulation of the anti‐apoptotic Bcl‐2 protein and stabilized the mitochondrial membrane potential (Δψm). MHC‐I ligation also prevented downregulation of Bcl‐2 and destabilization of Δψm induced by anti‐Fas Ab treatment or anisomycin exposure. Studies on three different Jurkat cell mutants deficient for src p56lck, ZAP‐70 kinase, or TCR/CD3 γ‐chain showed that the cells undergo apoptosis after Fas ligation. Anisomycin exposure induced apoptosis in the src p56lck‐deficient cell line but not in the two other mutant cell lines. Simultaneous cross‐linking of MHC‐I and Fas ligation inhibited apoptosis in the ZAP‐70 kinase and the TCR/CD3 γ‐chain mutants, but did not protect the src p56lck‐deficient cells. Similarly, MHC‐I ligation did not protect anisomycin‐treated src p56lck‐deficient cells against apoptosis. These data suggest that MHC‐I‐induced inhibition of apoptosis depends on intact src p56lck activity, but not on major secondary messenger molecules associated with TCR signaling. Overall the results support the idea that signal transduction by MHC‐I molecules is involved in homeostatic processes of importance for T‐cell survival and death.
- 1 September 2001
- Published by Wiley in Tissue Antigens
- Vol. 58 (3) , 171-180
Ligation of major histocompatibility complex class I antigens (MHC‐I) prevents apoptosis induced by Fas or SAPK/JNK activation in T‐lymphoma cells
Early apoptosis in Jurkat T‐lymphoma cells was induced by agonistic anti‐Fas Ab or by anisomycin which activates the stress kinases SAPK/JNK. Apoptosis was inhibited by ligation of major histocompatibility complex class I antigens (MHC‐I). MHC‐I ligation induced upregulation of the anti‐apoptotic Bcl‐2 protein and stabilized the mitochondrial membrane potential (Δψm). MHC‐I ligation also prevented downregulation of Bcl‐2 and destabilization of Δψm induced by anti‐Fas Ab treatment or anisomycin exposure. Studies on three different Jurkat cell mutants deficient for src p56lck, ZAP‐70 kinase, or TCR/CD3 γ‐chain showed that the cells undergo apoptosis after Fas ligation. Anisomycin exposure induced apoptosis in the src p56lck‐deficient cell line but not in the two other mutant cell lines. Simultaneous cross‐linking of MHC‐I and Fas ligation inhibited apoptosis in the ZAP‐70 kinase and the TCR/CD3 γ‐chain mutants, but did not protect the src p56lck‐deficient cells. Similarly, MHC‐I ligation did not protect anisomycin‐treated src p56lck‐deficient cells against apoptosis. These data suggest that MHC‐I‐induced inhibition of apoptosis depends on intact src p56lck activity, but not on major secondary messenger molecules associated with TCR signaling. Overall the results support the idea that signal transduction by MHC‐I molecules is involved in homeostatic processes of importance for T‐cell survival and death.